Related references
Note: Only part of the references are listed.Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
Seyoung Seo et al.
GASTRIC CANCER (2019)
Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status
Lei Wang et al.
CANCER MEDICINE (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
A randomized phase II study of weekly paclitaxel +/- trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
Akitaka Makiyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer
Sei Shu et al.
IN VIVO (2018)
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study
Filippo Pietrantonio et al.
CLINICAL CANCER RESEARCH (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma
Eiji Oki et al.
ONCOLOGY (2017)
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
N. Boku et al.
ANNALS OF ONCOLOGY (2017)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Gastric Cancer, Version 3.2016
Jaffer A. Ajani et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Christine Boeger et al.
ONCOTARGET (2016)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer
Yung-Jue Bang
JOURNAL OF CLINICAL GASTROENTEROLOGY (2012)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Share Paper
